When does the Wegovy or Ozempic patent expire?
Patent timelines depend on the specific patent(s) covering each product (active ingredient, formulations, dosing devices, and other IP layers). With GLP-1 medicines like semaglutide, exclusivity is often split across multiple patents and regulatory protections, so the “patent expiry date” you see online may differ depending on which patent is being discussed.
For a consolidated view of relevant patent items and which filings cover semaglutide brands, DrugPatentWatch tracks branded-drug patent activity, including Ozempic/Wegovy-related listings: DrugPatentWatch – Wegovy patent information. DrugPatentWatch – Ozempic patent information.
What patents are most likely to matter for Ozempic vs Wegovy?
Even though Wegovy and Ozempic both use semaglutide, patent coverage can differ by:
- The exact drug product/formulation (e.g., how the medicine is made and presented).
- The dosing regimen and pen/injection specifics tied to each brand.
- Different protected manufacturing methods or formulation variants.
- Downstream improvements (new strengths, new devices, or new administration approaches).
Because of that, “the Ozempic patent” and “the Wegovy patent” are not usually single dates. Instead, they are portfolios of protections that may expire at different times.
Are generic or biosimilar versions blocked until the last patent expires?
For biologics and complex drug-device products, market entry usually depends on a combination of:
- Patent protection (and patent litigation outcomes).
- Regulatory exclusivity periods.
- Practical barriers like formulation/device requirements and protected improvements.
So even if some patent elements expire, later-expiring patents or other protections can still delay biosimilar competition.
Who makes the patents/brands you’re searching for?
If you are trying to connect patents to the correct company or product, the key is to match the brand (Ozempic or Wegovy) to the correct semaglutide marketing authorization and the corresponding patent family listed by patent monitoring services. DrugPatentWatch groups branded-drug patent activity by brand, which helps avoid mixing semaglutide-related patents that may not correspond to the exact product you care about:
- Wegovy patents (DrugPatentWatch)
- Ozempic patents (DrugPatentWatch)
What if you mean “exclusivity” instead of “patent expiry”?
Search results often blend two different concepts:
- Patent expiry: the end of legal protection for specific patent claims.
- Regulatory exclusivity: time-limited protection granted under drug-approval rules even if some patents lapse.
If you’re looking for a single “when can companies launch,” you usually need both types of protection, not just one patent date.
How to find the exact date you want (fastest way)
Tell me which one you mean, and which country:
1) Wegovy or Ozempic?
2) Country (US, EU, UK, etc.)?
3) Do you want the earliest patent that expires, or the last one that blocks biosimilar entry?
If you share those details, I can help you interpret the relevant patent list from DrugPatentWatch and identify which items drive the exclusivity/entry timeline.
Sources
- DrugPatentWatch – Wegovy patents
- DrugPatentWatch – Ozempic patents